BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Publication in Journal of Medicinal Chemistry Highlights Molecular Insight Pharmaceuticals’ Program for Targeting Prostate Cancer


12/30/2008 8:32:50 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today the publication of a preclinical study describing the synthesis and initial evaluation of two series of radiolabeled small molecules that target prostate-specific membrane antigen (PSMA), a validated molecular marker for prostate cancer. The lead compounds, MIP-1072 and MIP-1095, demonstrated high affinity and specific binding to PSMA on human prostate cancer cells, and the radiolabeled analogs provide the foundation for the Company’s Trofex prostate cancer molecular imaging program, which is currently undergoing an exploratory Phase 1 clinical trial in patients with histological confirmed prostate cancer and evidence of recurrent disease. The goal of the clinical trial is to select the more promising of the two compounds for further clinical development and commercialization.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES